Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.

被引：3
|
作者：
Peng, Zhi
Zhang, Xiaotian
Liang, Han
Zheng, Zhichao
Wang, Zhenning
Liu, Hao
Hu, Jiankun
Sun, Yihong
Zhang, Yanqiao
Yan, Han
Tong, Lin
Xu, Jiahui
Xie, Jessica
Ji, Jiafu
Shen, Lin
机构：
[1] Peking Univ, Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res,Dept Gastro, Beijing, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[3] Liaoning Canc Hosp, Shenyang, Peoples R China
[4] China Med Univ, Hosp 1, Dept Surg Oncol, Shenyang, Peoples R China
[5] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[6] Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Precis Med Gastrointestina, Guangzhou, Guangdong, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[8] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[10] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[11] Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China
[12] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-424-6846-174; 261-492-2769; 283-2511; 261-566-148-2649; 281-318-430; 283-424-6846-5514; 261-566-9690; 6; 4; 3; 2; 291; 1791; 1854; 1704; 239; 92; 5; 38092-22447;
D O I：
10.1200/JCO.2024.42.3_suppl.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [1] FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study
    Pan, Hongming
    Yuan, Xiang-lin
    Zheng, Yu
    Peng, Hui
    Qiu, Hong
    Wang, Jufeng
    Li, Zhiwei
    Gao, Shegan
    Niu, Zuoxing
    Yang, Jianwei
    He, Yifu
    Wu, Guowu
    Yu, Yiyi
    Jieer, Ying
    Wang, Yusheng
    Li, Zhen
    Bai, Jun
    Liu, Huilong
    Wu, Zhuli
    Wang, Xingli
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
    Shitara, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Omuro, Y.
    Kawakami, H.
    Yabusaki, H.
    Sakamoto, Y.
    Nishina, T.
    Inaki, K.
    Kuwahara, Y.
    Suto, F.
    Sugihara, M.
    Saito, K.
    Kojima, A.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S224 - S224
  • [3] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-hee
    Sakai, Daisuke
    Chung, Hyun Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study
    Wang, Feng
    Liu, Tian-Shu
    Yuan, Xiang-Lin
    Luo, Hui-Yan
    Gu, Kang-Sheng
    Yuan, Ying
    Deng, Yan-Hong
    Xu, Jian-Ming
    Bai, Yu-Xian
    Wang, Ying
    Liao, Wang-Jun
    Zhang, He-Long
    Bi, Feng
    Wang, Bang-Mao
    Zhuang, Zhi-Xiang
    Jiang, Teng-Jia
    Xu, Rui-Hua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 3037 - +
  • [5] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
    Yamaguchi, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S235 - S235
  • [6] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
    Kohei Shitara
    Kensei Yamaguchi
    Kei Muro
    Hisateru Yasui
    Daisuke Sakai
    Takashi Oshima
    Masahiro Fujimura
    Yuta Sato
    Shunsuke Yamazaki
    Tatsuya Wakabayashi
    Masahiro Sugihara
    Takahiro Kamio
    Hirokazu Shoji
    International Journal of Clinical Oncology, 2024, 29 : 27 - 35
  • [7] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
    Shitara, Kohei
    Yamaguchi, Kensei
    Muro, Kei
    Yasui, Hisateru
    Sakai, Daisuke
    Oshima, Takashi
    Fujimura, Masahiro
    Sato, Yuta
    Yamazaki, Shunsuke
    Wakabayashi, Tatsuya
    Sugihara, Masahiro
    Kamio, Takahiro
    Shoji, Hirokazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (01) : 27 - 35
  • [8] Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Ding, Ya
    Chen, Yong-Ming
    Li, Yuan-Fang
    Liang, Cheng-Cai
    Cai, Mu-Yan
    Chen, Guo-Ming
    Wang, Wei
    Sun, Xiao-Wei
    Weng, De-Sheng
    Li, Dan-Dan
    Zhao, Jing-Jing
    Chen, Xiao-Jiang
    Guan, Yuan-Xiang
    Liu, Zhi-Min
    Liang, Yao
    Luo, Ma
    Chi, Jun
    Qiu, Hai-Bo
    Zhou, Zhi-Wei
    Zhang, Xiao-Shi
    Chen, Ying-Bo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [9] Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
    Fanucci, Kristina A.
    Pilat, Mary Jo
    Shyr, Derek
    Shyr, Yu
    Boerner, Scott A.
    Durecki, Diane
    Noonan, Anne
    Abramson, Vandana
    Santa-Maria, Cesar
    Han, Hyo
    Nanda, Rita
    Dees, Elizabeth Claire
    Park, Haeseong
    Buys, Saundra
    Peswani, Namrata
    Chew, Helen
    Assad, Hadeel
    Wulf, Gerburg
    Richardson, Angelique
    Trivedi, Meghna S.
    Brufsky, Adam
    Abbruzzese, James
    Afghahi, Anosheh
    Sharon, Elad
    Schalper, Kurt
    LoRusso, Patricia
    CANCER RESEARCH, 2023, 83 (08)
  • [10] A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
    Shitara, K.
    Bang, Y-J.
    Sakai, D.
    Yasui, H.
    Kawaguchi, Y.
    Sugihara, M.
    Saito, K.
    Dalal, R.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 65 - 65
12345